Physician profile
Kena Shah
NPI 1356604169
$5,513.29
in general payments reported to CMS, 2019-2025
29 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $170 · 2021: $1,491 · 2022: $956 · 2023: $214 · 2024: $896 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374 · Consulting Fee: $50.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.96 |
| Consulting Fee | $50.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $748.40 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $666.06 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Optinose US, INC. | $503.80 | 2019-2025 | |
| Alk-Abello, INC | $443.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $382.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $364.33 | 2019-2025 | Dupixent |
| Genzyme Corporation | $332.65 | 2019-2022 | |
| Amgen INC. | $301.72 | 2021-2025 | Tezspire |
| Pfizer INC. | $299.90 | 2019-2024 | |
| Csl Behring | $291.33 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Biocryst US Sales Co., LLC | $268.08 | 2022-2025 | Orladeyo |
| Grifols USA, LLC | $144.59 | 2021-2025 | Xembify |
| Kaleo, INC. | $139.95 | 2022-2024 | Auvi-Q |
| Ucb, INC. | $125.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.74 | 2021-2025 | Cuvitru |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $51.19 | 2021 | |
| Adma Biomanufacturing LLC | $50.43 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $44.92 | 2025 | Neffy |
| Genentech USA, INC. | $43.78 | 2024-2025 | Xolair |
| Octapharma USA, INC. | $43.28 | 2024-2025 | Cutaquig, Panzyga |
| Horizon Therapeutics Plc | $28.32 | 2021 | |
| Pharming Healthcare, INC. | $26.98 | 2021 | |
| Paratek Pharmaceuticals, INC. | $23.87 | 2025 | Xhance |
| Galderma Laboratories, L.P. | $22.63 | 2025 | Nemluvio |
| Phadia US INC. | $20.44 | 2020 | |
| Ionis Pharmaceuticals, INC. | $20.05 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $16.71 | 2025 | Sajazir |
| Incyte Corporation | $15.67 | 2022 | |
| Organon LLC | $13.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kena Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.